1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

US FDA Ready To Move Forward On Developing Quality Management Maturity Rating System

 
• By Michael McCaughan

The US FDA will begin work on operationalizing a Quality Management Maturity rating system following a public vote of confidence from its outside advisory committee. There are plenty of key details still to be worked out.

Filling in the blanks
fda will fill in the blanks on qmm • Source: Shutterstock

The US Food and Drug Administration will move into the process of drafting an implementable Quality Management Maturity rating system after a 2 November public endorsement of the concept from its Pharmaceutical Science & Clinical Pharmacology Advisory Committee.

The committee review amounted to the final stop on FDA’s process to build support at the conceptual level for the QMM proposal. FDA kicked off the 2022 campaign with a white paper issued in April, followed by a two-day workshop to report on pilot tests conducted in 2020 and 2021. The November advisory committee was announced as a capstone event when the white paper was released

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

US FDA’s Expanded Surprise Foreign Inspections: Impact And Enforcement Hoops

 
• By Anju Ghangurde

As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.

More from Compliance